Showing 5271-5280 of 7125 results for "".
- Update: Two More Payers to Cover DermTech’s Melanoma Testhttps://practicaldermatology.com/news/update-two-more-payers-to-cover-dermtechs-melanoma-test/2461514/Two new payers plan to cover the DermTech Melanoma Test, making the foundational assay available to approximately 1.2 million more people. The new insurers are Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. T
- Twenty New Products Earn NPF Seal of Recognitionhttps://practicaldermatology.com/news/twenty-new-products-earn-npf-seal-of-recognition/2461512/Twenty new products have earned the National Psoriasis Foundation’s Seal of Recognition. Each of these 20 products passed the same rigorous application, review, and approval process as the other 45 products that comprise the
- First Patient Dosed in Phase II Clinical Trial of TLL018-205 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-ii-clinical-trial-of-tll018-205-for-pso/2461511/The first patient has been enrolled and dosed in a Phase II study evaluating the efficacy and safety of TLL-018 fpr moderate to severe plaque psoriasis. This study is sponsored by Hangzhou Highlightll Pharmaceutical Co., Ltd (Highlightll Pharmaceutical, USA). T
- Journey Medical Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosaceahttps://practicaldermatology.com/news/journey-medical-completes-enrollment-in-phase-3-clinical-trials-evaluating-dfd-29-for-the-treatment-of-papulopustular-rosacea/2461506/Journey Medical Corp. announced that it has fully enrolled and randomized all of the patients in its Phase 3 clinical program to assess the safety, efficacy and tolerability of DFD-29 (minocycline modified release capsules 40 mg) for the treatment of papulopustular rosacea, the company announced
- AAD Issues Updated Guidelines for the Management of Atopic Dermatitis in Adults with Topical Therapieshttps://practicaldermatology.com/news/aad-issues-updated-guidelines-for-the-management-of-atopic-dermatitis-in-adults-with-topical-therapies/2461499/The American Academy of Dermatology (AAD) has published updated guidelines of care for the management of atopic dermatitis in adults with topical therapies in the Journal of the American Academy
- Dr. B Expands Telehealth Service into Dermatologyhttps://practicaldermatology.com/news/dr-b-expands-telehealth-service-into-dermatology/2461498/Telehealth service Dr. B added several specialties to it service network, including dermatology. The move allows patients to access low or no-cost virtual doctor consultations for a variety of conditions from home. Dr. B’s online consultation fee is $15 for paying p
- Can-Fite Submits Market Registration Plan for Psoriasis Treatment Piclidenoson in Europe; FDA Submission to Followhttps://practicaldermatology.com/news/can-fite-submits-market-registration-plan-for-psoriasis-treatment-piclidenoson-in-europe-fda-submission-to-follow/2461494/Can-Fite BioPharma announced it has submitted a market registration plan to the European Medicines Agency (EMA) for its lead drug candidate Piclidenoson in the treatment of moderate to severe psoriasis. The company said a submission to the FDA will follow. Piclidenoson is a no
- Study Reveals Novel Insights on Melanin Formationhttps://practicaldermatology.com/news/study-reveals-novel-insights-on-melanin-formation/2461491/“Nrf3” regulates the process of melanin production in mouse and human cells, a new study shows. NF-E2-related factor 3 or “Nrf3,” a known transcription factor, or protein involved in the pro
- Aditxt Forms Adimune, Inc.; Appoints Dr. Friedrich Kapp as Chairman and CEOhttps://practicaldermatology.com/news/aditxt-forms-adimune-inc-appoints-dr-friedrich-kapp-as-chairman-and-ceo/2461479/Aditxt, Inc. has formed Adimune
- Apyx Medical Launches #ThisIsMe Campaign for Renuvionhttps://practicaldermatology.com/news/apyx-medical-launches-thisisme-campaign-for-renuvion/2461478/Apyx Medical Corporation is rolling out its first-ever direct-to-consumer brand campaign for Renuvion, a proprietary helium plasma and radiofrequency technology. The #ThisIsMe campaign is aimed at U.S. consumers who are interested in a minimally invas